Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – 9,10-seco- cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-07-04
2006-07-04
Badio, Barbara P. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
9,10-seco- cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
active
07071178
ABSTRACT:
Compounds of the formula IwhereinX represents hydrogen or hydroxy;Y represents oxygen or sulphur or oxidized sulphur selected from the groups S(O) and S(O2);R1and R2, which may be the same or different, represent hydrogen or a residue after removal of 1 hydrogen atom from a straight, branched or cyclic, saturated or unsaturated, C1–C6-hydrocarbon; or R1and R2, together with the carbon atom to which they are attached (marked with an asterisk in formula I), bearing the group X, form a C3–C8carbocyclic ring;Q represents a diradical residue after removal of 2 hydrogen atoms from a straight, branched or cyclic, saturated or unsaturated C1–C8-hydrocarbon; andR3represents hydrogen or a residue after removal of 1 hydrogen atom from a straight, branched or cyclic, saturated or unsaturated C1–C6-hydrocarbon;may be used for the preparation of a medicament for the treatment and/or prophylaxis of osteoporosis and related bone disorders.
REFERENCES:
patent: 3163836 (1964-12-01), Sugi et al.
patent: 3588317 (1971-06-01), Hutchins, Jr.
patent: 4849288 (1989-07-01), Schmaderer et al.
patent: 5374629 (1994-12-01), Calverley et al.
patent: 5929385 (1999-07-01), Sugimoto et al.
patent: 5952614 (1999-09-01), Ries
patent: 0 567 353 (1993-10-01), None
patent: WO 91/15475 (1991-10-01), None
patent: WO 96/39705 (1996-12-01), None
D'Armour, “The role of parathyroid hormone and hyperparathyroidism in osteoporosis.” Osteoporosis Primer, 2000, 211-224. Abstract attached.
Fukunaga, “Characteristics of bone mass change in secondary osteoporosis.” Clinical Calcium, 1994, vol. 4(8), 1099-1101. Abstract attached.
Kurabayashi, “Developmental mechanism and management of osteoporosis induced by endocrine disorder.” Rinsho to Yakubutsu Chiryo, 1995, vol. 14(6), 521-524. Abstract attached.
Binderup Ernst Torndal
Grue-Sørensen Gunnar
Pedersen Henrik
Tranholm Mikael
Badio Barbara P.
Birch & Stewart Kolasch & Birch, LLP
Leo Pharmaceutical Products Ltd.
LandOfFree
Use of vitamin D-derivatives in the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of vitamin D-derivatives in the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of vitamin D-derivatives in the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3603122